Group 1 - The core viewpoint of the news is that Innovation Medical's stock has experienced significant fluctuations, with a year-to-date increase of 33.66% but a recent decline of 18.11% over the past five trading days [1] - As of January 20, the stock price was 28.75 yuan per share, with a total market capitalization of 12.687 billion yuan [1] - The company has seen a net outflow of 14.05 million yuan in principal funds, with large orders showing a buy of 57.736 million yuan and a sell of 72.818 million yuan [1] Group 2 - Innovation Medical operates primarily in the medical services sector, with 99.73% of its revenue coming from medical services and only 0.27% from other sources [1] - As of September 30, the number of shareholders increased by 58.75% to 130,200, while the average circulating shares per person decreased by 37.01% to 3,196 shares [2] - For the period from January to September 2025, the company reported a revenue of 597 million yuan, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders increased by 116.97% to 4.7244 million yuan [2]

Group 1 - The core viewpoint of the news is that Innovation Medical has shown significant stock performance and trading activity, with a year-to-date increase of 169.97% in stock price and notable trading volumes [1][2] - As of December 24, the stock price reached 21.49 CNY per share, with a total market capitalization of 9.483 billion CNY and a trading volume of 302 million CNY [1] - The company has seen a net inflow of 15.23 million CNY from major funds, indicating strong investor interest [1] Group 2 - Innovation Medical operates primarily in the medical services sector, with 99.73% of its revenue coming from medical services and only 0.27% from other sources [1] - As of September 30, the number of shareholders increased to 130,200, a rise of 58.75%, while the average number of circulating shares per person decreased by 37.01% [2] - For the period from January to September 2025, the company reported a revenue of 597 million CNY, a year-on-year decrease of 2.11%, while the net profit attributable to the parent company was 4.7244 million CNY, reflecting a significant increase of 116.97% [2] Group 3 - Since its A-share listing, Innovation Medical has distributed a total of 55.8729 million CNY in dividends, but there have been no dividend distributions in the past three years [3]

Core Insights - Innovation Medical's stock price decreased by 2.03% on November 19, trading at 21.24 CNY per share with a total market capitalization of 9.373 billion CNY [1] - The company has seen a significant stock price increase of 166.83% year-to-date, but has experienced declines of 9.50% over the last five trading days, 9.69% over the last twenty days, and 14.49% over the last sixty days [1] - The company has been active in the stock market, appearing on the "Dragon and Tiger List" 19 times this year, with the most recent appearance on October 20, where it recorded a net buy of 242 million CNY [1] Financial Performance - For the period from January to September 2025, Innovation Medical reported a revenue of 597 million CNY, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders was 4.7244 million CNY, reflecting a year-on-year increase of 116.97% [2] - The company has a primary business focus on medical services, which accounts for 99.73% of its revenue, with other income contributing only 0.27% [1] Shareholder Information - As of September 30, the number of shareholders for Innovation Medical reached 130,200, an increase of 58.75% from the previous period, while the average number of circulating shares per shareholder decreased by 37.01% to 3,196 shares [2] Dividend Information - Since its A-share listing, Innovation Medical has distributed a total of 55.8729 million CNY in dividends, with no dividends paid in the last three years [3]

Core Viewpoint - Innovation Medical's stock has experienced significant volatility, with a year-to-date increase of 184.67% but a recent decline of 13.18% over the past five trading days [1] Group 1: Stock Performance - As of November 10, Innovation Medical's stock price was 22.66 CNY per share, with a market capitalization of 10 billion CNY [1] - The stock has seen a trading volume of 315 million CNY and a turnover rate of 3.28% [1] - Year-to-date, the stock has been on the leaderboard 19 times, with the most recent net purchase of 242 million CNY on October 20 [1] Group 2: Financial Performance - For the period from January to September 2025, Innovation Medical reported a revenue of 597 million CNY, a year-on-year decrease of 2.11% [2] - The net profit attributable to the parent company was 4.72 million CNY, reflecting a year-on-year increase of 116.97% [2] Group 3: Shareholder Information - As of September 30, the number of shareholders increased to 130,200, a rise of 58.75% from the previous period [2] - The average number of circulating shares per shareholder decreased by 37.01% to 3,196 shares [2] Group 4: Dividend Information - Since its A-share listing, Innovation Medical has distributed a total of 55.87 million CNY in dividends, with no dividends paid in the last three years [3]

Group 1 - The core viewpoint of the news is that Innovation Medical has shown significant stock performance with a year-to-date increase of 203.77%, despite a recent decline of 3.36% over the last five trading days [1] - As of November 6, the stock price reached 24.18 CNY per share, with a total market capitalization of 10.67 billion CNY [1] - The company has been actively traded, appearing on the "龙虎榜" (Dragon and Tiger List) 19 times this year, with the latest appearance on October 20, where it recorded a net buy of 242 million CNY [1] Group 2 - Innovation Medical operates primarily in the medical services sector, with 99.73% of its revenue coming from medical services and only 0.27% from other sources [1] - As of September 30, the number of shareholders increased to 130,200, a rise of 58.75%, while the average circulating shares per person decreased by 37.01% to 3,196 shares [2] - For the period from January to September 2025, the company reported a revenue of 597 million CNY, a year-on-year decrease of 2.11%, while the net profit attributable to the parent company was 4.72 million CNY, reflecting a year-on-year increase of 116.97% [2]

Core Viewpoint - Innovation Medical's stock has experienced significant fluctuations, with a year-to-date increase of 176.63% but a recent decline in the last five trading days by 9.68% [1] Financial Performance - As of June 30, 2023, Innovation Medical reported a revenue of 402 million yuan, a year-on-year decrease of 1.60%, while the net profit attributable to shareholders was -11.36 million yuan, an increase of 29.12% year-on-year [2] - The company has distributed a total of 55.87 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [2] Stock Market Activity - On September 22, 2023, Innovation Medical's stock price was 22.02 yuan per share, with a trading volume of 557 million yuan and a turnover rate of 5.99%, resulting in a total market capitalization of 9.717 billion yuan [1] - The stock has appeared on the "Dragon and Tiger List" 18 times this year, with the most recent appearance on September 5, 2023, showing a net buy of -121 million yuan [1] Shareholder Information - As of June 30, 2023, the number of shareholders for Innovation Medical was 82,000, an increase of 20.38% from the previous period, with an average of 5,074 circulating shares per shareholder, a decrease of 16.93% [2] Industry Classification - Innovation Medical is classified under the pharmaceutical and biological industry, specifically in the medical services sector, with concepts including ophthalmology, strong annual performance, QFII holdings, medical devices, and artificial intelligence [2]

8月13日，创新医疗盘中上涨5.34%，截至09:34，报21.69元/股，成交6.49亿元，换手率7.36%，总市值 95.71亿元。 资料显示，创新医疗管理股份有限公司位于浙江省诸暨市山下湖镇郑家湖村，公司的主营业务是提供医 疗服务，旗下包括建华医院、康华医院、福恬医院和明珠医院四家医疗机构，致力于满足患者需求和提 高医疗质量。公司通过精细化管理，科室建设，人才引培等方式以提升核心竞争力，同时关注行业政 策，进行供应链整合，以优化医疗资源和提高治疗效果。 2025年1月-6月，创新医疗实现营业收入4.02亿元，同比减少1.60%；归属净利润-1136.13万元，同比增 长29.12%。 截至6月30日，创新医疗股东户数8.2万，人均流通股5074股。 ...

截至3月31日，创新医疗股东户数6.82万，人均流通股6108股。 2025年1月-3月，创新医疗实现营业收入1.93亿元，同比减少3.98%；归属净利润-1393.74万元，同比减 少368.03%。 资料显示，创新医疗管理股份有限公司位于浙江省诸暨市山下湖镇郑家湖村，公司的主营业务是提供医 疗服务，旗下包括建华医院、康华医院、福恬医院和明珠医院四家医疗机构，致力于满足患者需求和提 高医疗质量。公司通过精细化管理，科室建设，人才引培等方式以提升核心竞争力，同时关注行业政 策，进行供应链整合，以优化医疗资源和提高治疗效果。 8月12日，创新医疗盘中上涨5.13%，截至09:54，报19.68元/股，成交10.33亿元，换手率13.13%，总市 值86.84亿元。 ...

上海市锦天城律师事务所 关于创新医疗管理股份有限公司 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 法律意见书 致：创新医疗管理股份有限公司 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于创新医疗管理股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受创新医疗管理股份有限 公司（以下简称"公司"或"创新医疗"）委托，就公司召开 2025 年第一次临时 股东大会（以下简称"本次股东大会"）的有关事宜，根据《中华人民共和国公 司法》 （以下简称"《公司法》"）、 《上市公司股东会规则》等法律、法规、规章和 其他规范性文件以及《创新医疗管理股份有限公司章程》 （以下简称"《公司章程》"） 的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核查了本所认为 ...